Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NANO-GROWTH

Financiado

An innovative non invasive and de risked system to enable the transdermal deliv...

An innovative non invasive and de risked system to enable the transdermal delivery of fragile therapeutic compounds for a better management of painful diseases Chronic pain affects +1.5 billion people worldwide, which means that pain affects more people than diabetes, heart disease and cancer combined. Since chronic pain persists for years, it becomes unbearable. Chronic pain is often th... ver más

31/05/2017

ASTRACIME

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

ASTRACIME Cnae: 6832. objeto: construcción completa, reparación y conservación de inmuebles, en especial de quirófanos médicos completamente equipados...

Sin perfil tecnológico

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-05-31

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 70% 100%

1 Participantes

ASTRACIME
50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Política de Cookies

Términos y Condiciones de uso

Política de privacidad

Aviso Legal

Innovating.Works @Copyright . Todos los derechos reservados.

Duración del proyecto: 4 meses Fecha Inicio: 2017-01-23
Fecha Fin: 2017-05-31

Líder del proyecto

ASTRACIME Cnae: 6832. objeto: construcción completa, reparación y conservación de inmuebles, en especial de quirófanos médicos completamente equipados...

Sin perfil tecnológico

Presupuesto del proyecto 71K€

Descripción del proyecto Chronic pain affects +1.5 billion people worldwide, which means that pain affects more people than diabetes, heart disease and cancer combined. Since chronic pain persists for years, it becomes unbearable. Chronic pain is often the result from neuropathy (nerve damage), which increases with age but also due to chronic diseases. For instance, 34% of diabetes cases develop painful neuropathy, which means 143 million people affected globally. Since there is no cure, patients receive analgesics and other meds for pain relief. To avoid inflicting further pain, medication is administered transdermally using topical solutions like creams or patches. However, there are important barriers to the dermal delivery of analgesics: scarcity of viable compounds, high biodegradation rate, short effect, poor efficiency and severe adverse effects. In response, we at Astracime have developed an innovative solution that overcomes the limitations of transdermal pain relief. This NANO-GROWTH project aims to bring to market a unique dermal patch loaded with encapsulated therapeutic compounds. The customized capsule protects the integrity of the compounds as they travel through the skin layers and bloodstream. In addition, we have engineered the capsule to provide target-mediated release. Altogether, our method secures a longer and safer pain relief. After been proven at the lab scale, we now aim to take a step further towards the mature stage. Thus, in Phase 1 we aim to assess the subsequent steps needed to secure this project from all technical, commercial and financial perspectives. This project encloses significant growth potential for Astracime, allowing us to consolidate a leader position in the field of pain management. Indeed, we expect to gain €41 million in revenues and hire 30 new people in 5 years. In turn, this project will contribute to improve the quality of life of millions of patients suffering from pain, while helping to reduce costs to our saturated healthcare system.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores